Paniz Pourpashang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paniz Pourpashang has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Arefeh Zahmatkesh
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 shared publications - Hamid Nasri
Department of Natural Sciences, The University of Georgia, Tbilisi, Georgia
3 shared publications - Sayed Yousef Mojtahedi
Pediatric Chronic Kidney Disease Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Elham Ahmadipour
Independent Researcher, Private Clinic, Pezeshkan Street, Alvand Building, Shiraz, Iran
2 shared publications - Maede Safari
Urology Department, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran
2 shared publications Maryam Ghodsi
Department of Pediatric Nephrology, School of Medicine, Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50263
Evaluating the efficacy and safety of macrolide therapy in primary ciliary dyskinesia
Background: Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterized by impaired ciliary function, defective mucociliary clearance, recurrent respiratory infections, and progressive respiratory morbidity. Macrolides, particularly azithromycin, have antibacterial, anti-inflammatory, and immunomodulatory properties and may therefore provide therapeutic benefit in PCD. This systematic review evaluated the efficacy and safety of macrolide therapy in patients with PCD. Methods: This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and was prospectively registered in International Prospective Register of Systematic Reviews (CRD42024553793). PubMed, Scopus, Web of Science, Embase, Cochrane, and Google Scholar were searched for studies published from January 1, 1990, to June 18, 2024. Eligibility criteria were defined using the population, intervention, comparator, outcomes, and study design framework. Study selection, data extraction, and risk of bias assessment were performed independently by 3 reviewers. A meta-analysis was not performed because of substantial methodological heterogeneity across the included studies. Results: Of 765 records identified, 9 studies met the inclusion criteria. These included 2 in vitro studies and 7 clinical studies, comprising case reports, case series, retrospective observational studies, and 1 randomized, placebo-controlled phase 3 trial. Across the clinical studies, sample sizes ranged from 1 to 90 participants. Overall, the available evidence suggested that macrolide therapy, particularly azithromycin, may reduce respiratory exacerbations and improve selected clinical symptoms in patients with PCD. Mechanistic in vitro evidence further indicated that azithromycin may reduce pro-inflammatory cytokine production and promote epithelial barrier repair. However, the included studies varied considerably in design, population characteristics, treatment protocols, and outcome definitions. Conclusion: Macrolides, especially azithromycin, may have a beneficial role in the management of PCD by reducing respiratory exacerbations, improving selected symptoms, and modulating airway inflammation. Nevertheless, the certainty of evidence remains limited by methodological heterogeneity, small sample sizes, and the scarcity of randomized controlled trials. Further large-scale, well-designed, PCD-specific clinical studies are required to confirm these preliminary findings and establish standardized treatment protocols.
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50263
Open AccessEvaluating the efficacy and safety of macrolide therapy in primary ciliary dyskinesia
Background: Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterized by impaired ciliary function, defective mucociliary clearance, recurrent respiratory infections, and progressive respiratory morbidity. Macrolides, particularly azithromycin, have antibacterial, anti-inflammatory, and immunomodulatory properties and may therefore provide therapeutic benefit in PCD. This systematic review evaluated the efficacy and safety of macrolide therapy in patients with PCD. Methods: This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and was prospectively registered in International Prospective Register of Systematic Reviews (CRD42024553793). PubMed, Scopus, Web of Science, Embase, Cochrane, and Google Scholar were searched for studies published from January 1, 1990, to June 18, 2024. Eligibility criteria were defined using the population, intervention, comparator, outcomes, and study design framework. Study selection, data extraction, and risk of bias assessment were performed independently by 3 reviewers. A meta-analysis was not performed because of substantial methodological heterogeneity across the included studies. Results: Of 765 records identified, 9 studies met the inclusion criteria. These included 2 in vitro studies and 7 clinical studies, comprising case reports, case series, retrospective observational studies, and 1 randomized, placebo-controlled phase 3 trial. Across the clinical studies, sample sizes ranged from 1 to 90 participants. Overall, the available evidence suggested that macrolide therapy, particularly azithromycin, may reduce respiratory exacerbations and improve selected clinical symptoms in patients with PCD. Mechanistic in vitro evidence further indicated that azithromycin may reduce pro-inflammatory cytokine production and promote epithelial barrier repair. However, the included studies varied considerably in design, population characteristics, treatment protocols, and outcome definitions. Conclusion: Macrolides, especially azithromycin, may have a beneficial role in the management of PCD by reducing respiratory exacerbations, improving selected symptoms, and modulating airway inflammation. Nevertheless, the certainty of evidence remains limited by methodological heterogeneity, small sample sizes, and the scarcity of randomized controlled trials. Further large-scale, well-designed, PCD-specific clinical studies are required to confirm these preliminary findings and establish standardized treatment protocols.
- Open Access
- 21 June 2026
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 15 (2) , e12876
Reviving the microcirculation; the protective role of SGLT2 inhibitors in counteracting capillary rarefaction
Capillary rarefaction, as the loss of microvascular density and architecture, is a hallmark of chronic tissue hypoxia seen in diabetes, hypertension, and various forms of chronic kidney and heart disease. It promotes inflammation, fibrosis, and eventual loss of organ function by diminishing oxygen delivery, nutrient exchange, and waste removal. In diabetic nephropathy, intrarenal hypoxia accelerates capillary rarefaction, creating a destructive feedback loop of progressive renal impairment. The restoration of microvascular integrity by SGLT2 inhibitors encompasses a series of glucose-independent actions, involving both metabolic and cellular signaling pathways. These compounds modulate the renal and systemic microcirculation through several key lines. Preclinical data demonstrate improved endothelial function, characterized by enhanced nitric oxide production, decreased oxidative stress, and normalized mitochondrial homeostasis. These drugs stimulate angiogenic pathways and endothelial cell viability, directly promoting the regeneration of microvessels and counteracting rarefaction. These agents have also been shown to attenuate inflammation within the microvasculature, reducing cytokine-driven vascular injury and remodeling. In both animal studies and early-phase clinical investigations, SGLT2 inhibitors foster improved vasodilation and hemodynamic stability, which are crucial to maintaining capillary networks.
- 21 June 2026
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 15 (2) , e12876
Open AccessReviving the microcirculation; the protective role of SGLT2 inhibitors in counteracting capillary rarefaction
Capillary rarefaction, as the loss of microvascular density and architecture, is a hallmark of chronic tissue hypoxia seen in diabetes, hypertension, and various forms of chronic kidney and heart disease. It promotes inflammation, fibrosis, and eventual loss of organ function by diminishing oxygen delivery, nutrient exchange, and waste removal. In diabetic nephropathy, intrarenal hypoxia accelerates capillary rarefaction, creating a destructive feedback loop of progressive renal impairment. The restoration of microvascular integrity by SGLT2 inhibitors encompasses a series of glucose-independent actions, involving both metabolic and cellular signaling pathways. These compounds modulate the renal and systemic microcirculation through several key lines. Preclinical data demonstrate improved endothelial function, characterized by enhanced nitric oxide production, decreased oxidative stress, and normalized mitochondrial homeostasis. These drugs stimulate angiogenic pathways and endothelial cell viability, directly promoting the regeneration of microvessels and counteracting rarefaction. These agents have also been shown to attenuate inflammation within the microvasculature, reducing cytokine-driven vascular injury and remodeling. In both animal studies and early-phase clinical investigations, SGLT2 inhibitors foster improved vasodilation and hemodynamic stability, which are crucial to maintaining capillary networks.
- 15 April 2026
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 15, e38747
Role of oxidative stress and reactive oxygen species in calcium oxalate kidney stone pathogenesis
Oxidative stress and reactive oxygen species (ROS) generation are central drivers of calcium oxalate kidney stone pathogenesis by promoting renal tubular epithelial cell injury, inflammation, cell death, and extracellular matrix remodeling, which collectively create a renal environment conducive to crystal deposition, retention, and stone growth. Targeting oxidative stress pathways with antioxidants and modulators of ROS production presents a promising avenue for therapeutic intervention to prevent kidney stone recurrence and progression. This insights from molecular, cellular, and pathophysiological studies showing that calcium oxalate crystals set off a cascade of oxidative and inflammatory events that culminate in kidney stone formation, and also accentuates the importance of maintaining redox balance and renal cellular health in mitigating the burden of calcium oxalate nephrolithiasis.
- 15 April 2026
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 15, e38747
Role of oxidative stress and reactive oxygen species in calcium oxalate kidney stone pathogenesis
Oxidative stress and reactive oxygen species (ROS) generation are central drivers of calcium oxalate kidney stone pathogenesis by promoting renal tubular epithelial cell injury, inflammation, cell death, and extracellular matrix remodeling, which collectively create a renal environment conducive to crystal deposition, retention, and stone growth. Targeting oxidative stress pathways with antioxidants and modulators of ROS production presents a promising avenue for therapeutic intervention to prevent kidney stone recurrence and progression. This insights from molecular, cellular, and pathophysiological studies showing that calcium oxalate crystals set off a cascade of oxidative and inflammatory events that culminate in kidney stone formation, and also accentuates the importance of maintaining redox balance and renal cellular health in mitigating the burden of calcium oxalate nephrolithiasis.
- Open Access
- 24 November 2025
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 51 (1)
The association between copeptin and hypertension in children and adolescents: a systematic review
Copeptin, a stable surrogate marker of arginine vasopressin, has been implicated in blood pressure regulation, but its role in pediatric hypertension remains unclear. This systematic review evaluates the association between copeptin levels and hypertension in children and adolescents. A comprehensive search was conducted in PubMed, Scopus, Web of Science, Embase, and Cochrane Library up to February 21, 2025. Additional sources, including Google Scholar and reference lists of relevant articles, were screened to ensure literature saturation. Observational studies (cohort, case-control, and cross-sectional) assessing copeptin levels in relation to blood pressure in pediatric populations (< 18 years) were included. Copeptin levels were assessed using validated biochemical methods, including enzyme-linked immunosorbent assay. The Newcastle-Ottawa Scale was used to assess the quality of included studies. Due to heterogeneity in study designs and outcome measurements, a narrative synthesis was performed. Twelve studies met the inclusion criteria, with sample sizes ranging from 25 to 351 participants. Some studies reported a significant association between higher copeptin levels and hypertension, particularly in children with obesity or metabolic disorders. However, other studies found no significant correlation. Differences in study design, sample characteristics, copeptin measurement methods, and confounding factors contributed to the heterogeneity of findings. The evidence on the association between copeptin and hypertension in children is inconclusive. While some studies support its potential role as a biomarker, inconsistencies highlight the need for standardized methodologies and longitudinal studies. Future research should explore copeptin’s clinical utility in pediatric hypertension risk stratification. Systematic review registration number PROSPERO: CRD420251003190.
- 24 November 2025
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 51 (1)
Open AccessThe association between copeptin and hypertension in children and adolescents: a systematic review
Copeptin, a stable surrogate marker of arginine vasopressin, has been implicated in blood pressure regulation, but its role in pediatric hypertension remains unclear. This systematic review evaluates the association between copeptin levels and hypertension in children and adolescents. A comprehensive search was conducted in PubMed, Scopus, Web of Science, Embase, and Cochrane Library up to February 21, 2025. Additional sources, including Google Scholar and reference lists of relevant articles, were screened to ensure literature saturation. Observational studies (cohort, case-control, and cross-sectional) assessing copeptin levels in relation to blood pressure in pediatric populations (< 18 years) were included. Copeptin levels were assessed using validated biochemical methods, including enzyme-linked immunosorbent assay. The Newcastle-Ottawa Scale was used to assess the quality of included studies. Due to heterogeneity in study designs and outcome measurements, a narrative synthesis was performed. Twelve studies met the inclusion criteria, with sample sizes ranging from 25 to 351 participants. Some studies reported a significant association between higher copeptin levels and hypertension, particularly in children with obesity or metabolic disorders. However, other studies found no significant correlation. Differences in study design, sample characteristics, copeptin measurement methods, and confounding factors contributed to the heterogeneity of findings. The evidence on the association between copeptin and hypertension in children is inconclusive. While some studies support its potential role as a biomarker, inconsistencies highlight the need for standardized methodologies and longitudinal studies. Future research should explore copeptin’s clinical utility in pediatric hypertension risk stratification. Systematic review registration number PROSPERO: CRD420251003190.
- Open Access
- 9 November 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (2) , e43980
A novel gross deletion in SMARCAL1 impairs DNA replication fork regression, leading to severe Schimke immuno-osseous dysplasia; a literature review and an integrated study of clinical, genetic, and protein-protein interaction analysis
Schimke immuno-osseous dysplasia (SIOD) is an exceptionally rare autosomal recessive disorder that affects multiple organ systems, most notably the skeletal system, kidneys, and immune system. The clinical manifestations of SIOD include growth retardation, skeletal deformities, progressive proteinuria, and immunodeficiency. Severe cases may progress to nephrotic syndrome and cerebral infarctions. The disorder is primarily attributed to biallelic mutations in the SMARCAL1 gene, which leads to the early onset of symptoms and often results in premature mortality. In this study, we identified a novel gross deletion encompassing exons 5 and 6 of the SMARCAL1 gene. This deletion leads to a partial loss of the HARP1 and HARP2 domains and the generation of a novel HARP domain that is structurally similar to both HARP1 and HARP2, while retaining conserved amino acids. Our AlphaFold 3D modeling indicated that the truncated SMARCAL1 protein is identical to the wild-type SMARCAL1, except for the absence of HARP1 domain, and resembles invertebrate SMARCAL1, which naturally possesses only one HARP domain. Previous studies have demonstrated that human SMARCAL1 lacking the HARP1 domain retains normal helicase, ATPase, and DNA-binding activities. Additionally, invertebrate SMARCAL1, which also lacks the HARP1 domain, fails to effectively regress DNA replication forks. This suggests that the identified gross deletion may contribute to SIOD pathogenesis by impairing DNA replication fork regression and genomic instability
- 9 November 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (2) , e43980
Open AccessA novel gross deletion in SMARCAL1 impairs DNA replication fork regression, leading to severe Schimke immuno-osseous dysplasia; a literature review and an integrated study of clinical, genetic, and protein-protein interaction analysis
Schimke immuno-osseous dysplasia (SIOD) is an exceptionally rare autosomal recessive disorder that affects multiple organ systems, most notably the skeletal system, kidneys, and immune system. The clinical manifestations of SIOD include growth retardation, skeletal deformities, progressive proteinuria, and immunodeficiency. Severe cases may progress to nephrotic syndrome and cerebral infarctions. The disorder is primarily attributed to biallelic mutations in the SMARCAL1 gene, which leads to the early onset of symptoms and often results in premature mortality. In this study, we identified a novel gross deletion encompassing exons 5 and 6 of the SMARCAL1 gene. This deletion leads to a partial loss of the HARP1 and HARP2 domains and the generation of a novel HARP domain that is structurally similar to both HARP1 and HARP2, while retaining conserved amino acids. Our AlphaFold 3D modeling indicated that the truncated SMARCAL1 protein is identical to the wild-type SMARCAL1, except for the absence of HARP1 domain, and resembles invertebrate SMARCAL1, which naturally possesses only one HARP domain. Previous studies have demonstrated that human SMARCAL1 lacking the HARP1 domain retains normal helicase, ATPase, and DNA-binding activities. Additionally, invertebrate SMARCAL1, which also lacks the HARP1 domain, fails to effectively regress DNA replication forks. This suggests that the identified gross deletion may contribute to SIOD pathogenesis by impairing DNA replication fork regression and genomic instability
- Open Access
- 30 June 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (2) , e12771
The association between triglyceride-glucose index and contrast-induced nephropathy; a systematic review and meta-analysis
Introduction: The triglyceride-glucose index (TyG) is an indicator of insulin resistance, which can cause chronic dysfunction in renal performance. Accordingly, the present study aimed to examine the association between high TyG index levels and the risk of contrast-induced nephropathy (CIN) using systematic review and meta-analysis methods. Materials and Methods: Searches were conducted across several databases, including Web of Science, Cochrane Library, ProQuest, PubMed, Embase, and Google Scholar. Data was analyzed using STATA 14 software, and tests with P<0.05 were considered statistically significant. Results: High TyG index levels in total population (odds ratio [OR]: 2.24, 95% CI: 1.85, 2.71), in China (OR: 2.16, 95% CI: 1.76, 2.66), Turkey (OR: 2.77, 95% CI: 1.66, 4.6), cohort studies (OR: 2.13, 95% CI: 1.64, 2.78), case-control studies (OR: 2.59, 95% CI: 1.92, 3.51), and cross-sectional studies (OR: 2.17, 95% CI: 1.21, 3.89) increased the risk of CIN. On the other hand, the relationship between high TyG index levels among women (OR: 1.22, 95% CI: 0.84, 1.77) and CIN was insignificant. Furthermore, the association between high age (OR: 1.03, 95% CI: 1, 1.05), low-density lipoprotein (LDL) cholesterol (OR: 1.08, 95% CI: 1.03, 1.14), and eGFR (OR: 0.98, 95% CI: 0.96, 0.99) and the risk of CIN was statistically significant, but there was no significant relationship between blood hypertension (OR: 1.46, 95% CI: 0.95, 2.24), systolic blood pressure (SBP) (OR: 1.01, 95% CI: 0.99, 1.02), diastolic blood pressure (DBP) (OR: 1, 95% CI: 0.98, 1.03), diabetes mellitus (DM) (OR: 1.36, 95% CI: 0.58, 3.18), fasting blood glucose (FBG) (OR: 1.06, 95% CI: 0.97, 1.16), and hemoglobin (OR: 0.97, 95% CI: 0.94, 1.01) and the risk of CIN. Conclusion: High TyG index levels, high age, and LDL cholesterol levels increased the risk of CIN, indicating that the TyG index can be a strong predictor for the occurrence of CIN. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420250651085 )and Research Registry (UIN: reviewregistry1951) websites.
- 30 June 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (2) , e12771
Open AccessThe association between triglyceride-glucose index and contrast-induced nephropathy; a systematic review and meta-analysis
Introduction: The triglyceride-glucose index (TyG) is an indicator of insulin resistance, which can cause chronic dysfunction in renal performance. Accordingly, the present study aimed to examine the association between high TyG index levels and the risk of contrast-induced nephropathy (CIN) using systematic review and meta-analysis methods. Materials and Methods: Searches were conducted across several databases, including Web of Science, Cochrane Library, ProQuest, PubMed, Embase, and Google Scholar. Data was analyzed using STATA 14 software, and tests with P<0.05 were considered statistically significant. Results: High TyG index levels in total population (odds ratio [OR]: 2.24, 95% CI: 1.85, 2.71), in China (OR: 2.16, 95% CI: 1.76, 2.66), Turkey (OR: 2.77, 95% CI: 1.66, 4.6), cohort studies (OR: 2.13, 95% CI: 1.64, 2.78), case-control studies (OR: 2.59, 95% CI: 1.92, 3.51), and cross-sectional studies (OR: 2.17, 95% CI: 1.21, 3.89) increased the risk of CIN. On the other hand, the relationship between high TyG index levels among women (OR: 1.22, 95% CI: 0.84, 1.77) and CIN was insignificant. Furthermore, the association between high age (OR: 1.03, 95% CI: 1, 1.05), low-density lipoprotein (LDL) cholesterol (OR: 1.08, 95% CI: 1.03, 1.14), and eGFR (OR: 0.98, 95% CI: 0.96, 0.99) and the risk of CIN was statistically significant, but there was no significant relationship between blood hypertension (OR: 1.46, 95% CI: 0.95, 2.24), systolic blood pressure (SBP) (OR: 1.01, 95% CI: 0.99, 1.02), diastolic blood pressure (DBP) (OR: 1, 95% CI: 0.98, 1.03), diabetes mellitus (DM) (OR: 1.36, 95% CI: 0.58, 3.18), fasting blood glucose (FBG) (OR: 1.06, 95% CI: 0.97, 1.16), and hemoglobin (OR: 0.97, 95% CI: 0.94, 1.01) and the risk of CIN. Conclusion: High TyG index levels, high age, and LDL cholesterol levels increased the risk of CIN, indicating that the TyG index can be a strong predictor for the occurrence of CIN. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420250651085 )and Research Registry (UIN: reviewregistry1951) websites.
- Open Access
- 22 June 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (2) , e12800
Application of the updated international IgA nephropathy prediction tool in pediatric patients
The International IgA Nephropathy Prediction Tool (IgAN-PT) aims to provide individualized risk assessments for patients diagnosed with primary IgAN, which is a prevalent cause of kidney disease, especially among young adults. This tool helps clinicians to understand the risk for worsening kidney function over a period of 5-7 years post-diagnosis. This scoring can be conducted by the physician at the time of diagnosis, while it requires only routine clinical data, laboratory results, and biopsy findings. This system also is applicable to adults and pediatrics of all ethnicities.
- 22 June 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14 (2) , e12800
Open AccessApplication of the updated international IgA nephropathy prediction tool in pediatric patients
The International IgA Nephropathy Prediction Tool (IgAN-PT) aims to provide individualized risk assessments for patients diagnosed with primary IgAN, which is a prevalent cause of kidney disease, especially among young adults. This tool helps clinicians to understand the risk for worsening kidney function over a period of 5-7 years post-diagnosis. This scoring can be conducted by the physician at the time of diagnosis, while it requires only routine clinical data, laboratory results, and biopsy findings. This system also is applicable to adults and pediatrics of all ethnicities.
- 22 May 2025
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 15 (1) , e38655
Global trends in kidney failure incidence over a 5-year period of 2019–2023; an ecological analysis of the International Society of Nephrology data
Introduction: Kidney failure, a critical global health issue, has shown varying trends in incidence across different regions over the past five years. Objectives: This ecological analysis examines data from the International Society of Nephrology (ISN) to identify the trend pattern of kidney failure incidence between 2019 and 2023 across the world. Methods: This ecological study was conducted to evaluate kidney failure incidence across 78 countries over a five-year period (2019–2023) using data from the ISN Global Kidney Health Atlas (GKHA). Data were sourced from the ISN-GKHA website and included information for 78 countries across 10 global regions. The analysis involved extracting datasets from 2019 and 2023 to calculate changes in kidney failure incidence, identifying regional and global trends. Results: The results indicated that high-income countries exhibited varying trends in kidney failure incidence. For instance, Taiwan, Korea, and Chile experienced significant increases, whereas the Czech Republic and Panama recorded decreases. In middle-income countries, the patterns were mixed; Indonesia, Mexico, and Tunisia show marked rises, while Ecuador and El Salvador reported notable declines. Meanwhile, countries like Bahrain, Egypt, Georgia, Iran, and South Africa demonstrated stable rates, potentially reflecting steady healthcare systems or reliable data collection practices. Conclusion: The incidence of kidney failure across countries revealed diverse trends influenced by income levels and healthcare systems. High-income countries demonstrated variability, with significant increases in Taiwan, Korea, and Chile, contrasted by declines in the Czech Republic and Panama. Middle-income nations exhibited mixed patterns, as Indonesia, Mexico, and Tunisia reported rising rates, while Ecuador and El Salvador experienced declines. The stability observed in countries such as Bahrain, Egypt, Georgia, Iran, and South Africa suggests consistent healthcare infrastructure or effective data collection practices. Registration: This study has been compiled based on data from the ISN-GKHA website, and its protocol was registered on the research registry (UIN: researchregistry11142) website (https://gkha.theisn.org/).
- 22 May 2025
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 15 (1) , e38655
Global trends in kidney failure incidence over a 5-year period of 2019–2023; an ecological analysis of the International Society of Nephrology data
Introduction: Kidney failure, a critical global health issue, has shown varying trends in incidence across different regions over the past five years. Objectives: This ecological analysis examines data from the International Society of Nephrology (ISN) to identify the trend pattern of kidney failure incidence between 2019 and 2023 across the world. Methods: This ecological study was conducted to evaluate kidney failure incidence across 78 countries over a five-year period (2019–2023) using data from the ISN Global Kidney Health Atlas (GKHA). Data were sourced from the ISN-GKHA website and included information for 78 countries across 10 global regions. The analysis involved extracting datasets from 2019 and 2023 to calculate changes in kidney failure incidence, identifying regional and global trends. Results: The results indicated that high-income countries exhibited varying trends in kidney failure incidence. For instance, Taiwan, Korea, and Chile experienced significant increases, whereas the Czech Republic and Panama recorded decreases. In middle-income countries, the patterns were mixed; Indonesia, Mexico, and Tunisia show marked rises, while Ecuador and El Salvador reported notable declines. Meanwhile, countries like Bahrain, Egypt, Georgia, Iran, and South Africa demonstrated stable rates, potentially reflecting steady healthcare systems or reliable data collection practices. Conclusion: The incidence of kidney failure across countries revealed diverse trends influenced by income levels and healthcare systems. High-income countries demonstrated variability, with significant increases in Taiwan, Korea, and Chile, contrasted by declines in the Czech Republic and Panama. Middle-income nations exhibited mixed patterns, as Indonesia, Mexico, and Tunisia reported rising rates, while Ecuador and El Salvador experienced declines. The stability observed in countries such as Bahrain, Egypt, Georgia, Iran, and South Africa suggests consistent healthcare infrastructure or effective data collection practices. Registration: This study has been compiled based on data from the ISN-GKHA website, and its protocol was registered on the research registry (UIN: researchregistry11142) website (https://gkha.theisn.org/).
- Open Access
- 8 March 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 14, e27613
Association between systemic immune-inflammation index and risk of chronic kidney disease; a systematic review and meta-analysis
Introduction: Inflammation is a hallmark feature of chronic kidney disease (CKD) and the systemic immune-inflammation index (SII) is a potent biomarker for assessing the inflammatory status. Taking note of these, the present systematic review and meta-analysis evaluated the correlation between SII and the risk for CKD. Materials and Methods: ProQuest, Embase, PubMed, Web of Science, Cochrane, and Google Scholar databases were searched until November 20, 2024, without any restriction applied. Data were analyzed in Stata v14.0. The results with P30 kg/m² (OR: 1.05; 95% CI: 1.01, 1.09). Conclusion: Elevated SII values enhanced the risk of CKD, and the SII-CKD association was intensified in females, Americans, and patients with DM, low eGFR, albuminuria, and obesity. Accordingly, high SII levels are a robust indicator of CKD prognosis. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024619311) and Research Registry (UIN: reviewregistry1925, ) websites.
- 8 March 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 14, e27613
Open AccessAssociation between systemic immune-inflammation index and risk of chronic kidney disease; a systematic review and meta-analysis
Introduction: Inflammation is a hallmark feature of chronic kidney disease (CKD) and the systemic immune-inflammation index (SII) is a potent biomarker for assessing the inflammatory status. Taking note of these, the present systematic review and meta-analysis evaluated the correlation between SII and the risk for CKD. Materials and Methods: ProQuest, Embase, PubMed, Web of Science, Cochrane, and Google Scholar databases were searched until November 20, 2024, without any restriction applied. Data were analyzed in Stata v14.0. The results with P30 kg/m² (OR: 1.05; 95% CI: 1.01, 1.09). Conclusion: Elevated SII values enhanced the risk of CKD, and the SII-CKD association was intensified in females, Americans, and patients with DM, low eGFR, albuminuria, and obesity. Accordingly, high SII levels are a robust indicator of CKD prognosis. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024619311) and Research Registry (UIN: reviewregistry1925, ) websites.
- Open Access
- 4 March 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14, e12764
Thrombotic microangiopathy in IgA nephropathy; new evidence and ideas
The Oxford classification for IgA nephropathy (IgAN) does not currently include thrombotic microangiopathy (TMA) as a parameter, despite evidence that TMA can occur in IgAN patients and impact outcomes. Prior studies have found that a significant proportion of IgAN patients have histological evidence of TMA, either acute or organized, in their renal biopsies. Moreover, patients with TMA lesions in IgAN tend to have worse outcomes, including a greater percentage of sclerotic glomeruli, more tubulointerstitial fibrosis, and higher rates of doubling of serum creatinine or progression to end-stage renal disease compared to IgAN patients without TMA. Other researchers have suggested that TMA in IgAN is commonly located in the advanced steps of the disease and may be accompanying by severe hypertension and proteinuria. However, the Oxford system does not include TMA as a parameter. Therefore, further investigations are required to determine the clinical significance and optimal management of TMA in IgAN individuals. Renal arteriolar microangiopathic lesions can occur in immunoglobulin A nephropathy, but their role in disease progression has been unclear. Furthermore, the main limitation of the MEST-C classification is that it does not currently account for the presence and impact of TMA in IgAN, despite evidence that TMA is a common and clinically relevant histological finding in these patients.
- 4 March 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 14, e12764
Open AccessThrombotic microangiopathy in IgA nephropathy; new evidence and ideas
The Oxford classification for IgA nephropathy (IgAN) does not currently include thrombotic microangiopathy (TMA) as a parameter, despite evidence that TMA can occur in IgAN patients and impact outcomes. Prior studies have found that a significant proportion of IgAN patients have histological evidence of TMA, either acute or organized, in their renal biopsies. Moreover, patients with TMA lesions in IgAN tend to have worse outcomes, including a greater percentage of sclerotic glomeruli, more tubulointerstitial fibrosis, and higher rates of doubling of serum creatinine or progression to end-stage renal disease compared to IgAN patients without TMA. Other researchers have suggested that TMA in IgAN is commonly located in the advanced steps of the disease and may be accompanying by severe hypertension and proteinuria. However, the Oxford system does not include TMA as a parameter. Therefore, further investigations are required to determine the clinical significance and optimal management of TMA in IgAN individuals. Renal arteriolar microangiopathic lesions can occur in immunoglobulin A nephropathy, but their role in disease progression has been unclear. Furthermore, the main limitation of the MEST-C classification is that it does not currently account for the presence and impact of TMA in IgAN, despite evidence that TMA is a common and clinically relevant histological finding in these patients.